ProPhase Labs Statistics
Total Valuation
ProPhase Labs has a market cap or net worth of 1.05 million. The enterprise value is 9.58 million.
| Market Cap | 1.05M |
| Enterprise Value | 9.58M |
Important Dates
The last earnings date was Friday, May 15, 2026.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ProPhase Labs has 14.02 million shares outstanding. The number of shares has increased by 324.45% in one year.
| Current Share Class | 14.02M |
| Shares Outstanding | 14.02M |
| Shares Change (YoY) | +324.45% |
| Shares Change (QoQ) | +432.42% |
| Owned by Insiders (%) | 2.37% |
| Owned by Institutions (%) | 0.04% |
| Float | 13.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.24 |
| PB Ratio | 0.30 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.20 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.06, with a Debt / Equity ratio of 2.46.
| Current Ratio | 0.06 |
| Quick Ratio | 0.03 |
| Debt / Equity | 2.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.60 |
Financial Efficiency
Return on equity (ROE) is -430.66% and return on invested capital (ROIC) is -137.89%.
| Return on Equity (ROE) | -430.66% |
| Return on Assets (ROA) | -18.33% |
| Return on Invested Capital (ROIC) | -137.89% |
| Return on Capital Employed (ROCE) | -265.79% |
| Weighted Average Cost of Capital (WACC) | 57.15% |
| Revenue Per Employee | 228,684 |
| Profits Per Employee | -775,947 |
| Employee Count | 19 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 4.88 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.85% in the last 52 weeks. The beta is 0.07, so ProPhase Labs's price volatility has been lower than the market average.
| Beta (5Y) | 0.07 |
| 52-Week Price Change | -97.85% |
| 50-Day Moving Average | 0.11 |
| 200-Day Moving Average | 1.41 |
| Relative Strength Index (RSI) | 36.71 |
| Average Volume (20 Days) | 58,537 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.53 |
Income Statement
In the last 12 months, ProPhase Labs had revenue of 4.35 million and -14.74 million in losses. Loss per share was -1.74.
| Revenue | 4.35M |
| Gross Profit | 1.38M |
| Operating Income | -18.05M |
| Pretax Income | -23.39M |
| Net Income | -14.74M |
| EBITDA | -13.22M |
| EBIT | -18.05M |
| Loss Per Share | -1.74 |
Balance Sheet
The company has 90,000 in cash and 8.62 million in debt, with a net cash position of -8.53 million or -0.61 per share.
| Cash & Cash Equivalents | 90,000 |
| Total Debt | 8.62M |
| Net Cash | -8.53M |
| Net Cash Per Share | -0.61 |
| Equity (Book Value) | 3.51M |
| Book Value Per Share | 0.39 |
| Working Capital | -49.93M |
Cash Flow
| Operating Cash Flow | -8.34M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 4.83M |
| Net Borrowing | 3.31M |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 31.85% |
| Operating Margin | -415.35% |
| Pretax Margin | -538.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ProPhase Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -324.45% |
| Shareholder Yield | -324.45% |
| Earnings Yield | -1,402.49% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 22, 2025. It was a reverse split with a ratio of 0.1.
| Last Split Date | Dec 22, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
ProPhase Labs has an Altman Z-Score of -3.49 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.49 |
| Piotroski F-Score | 2 |